Phase I/II/III Pharmacokinetic and Outcome Study of Recombinant Factor IX Product, IB1001, in Subjects with Haemophilia B
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Trenonacog alfa (Primary)
- Indications Haemophilia B
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Aptevo Therapeutics; Emergent BioSolutions; Inspiration Biopharmaceuticals
- 30 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 May 2017.
- 13 Dec 2016 Planned End Date changed from 1 Nov 2014 to 1 Feb 2017.
- 17 Sep 2014 New trial record